share_log

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test With Retail Launch

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test With Retail Launch

万基遗传扩大在家早期胎儿性别DNA检测的可及性,并进行零售发布
GlobeNewswire ·  11/13 08:00

SneakPeek, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide

SneakPeek,首款可在六周使用的家庭早期胎儿性别测试,现在已经在全国800多家零售位置上市了

SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended gender test with over 99% accuracy,[1] is now available over the counter in more than 8,800 retail locations nationwide. The product is the first of its kind to be sold on shelf in Walmart stores greatly expanding access for expectant parents who want to learn if they're having a girl or boy at-home as early as six weeks into pregnancy.

盐湖城,2024年11月13日(GLOBE NEWSWIRE)-- 万基遗传公司(纳斯达克: MYGN),遗传测试和精准医学领域的领导者,继续为父母提供更多产前测试的机会。 SneakPeek作为1号妇产科医生推荐的性别测试,准确率超过99%[1],现已在全国800多家零售店可购买。这款产品是首款在沃尔玛门店货架上销售的产品,让期待中的父母可以在怀孕六周时在家了解他们是在期待男孩还是女孩,从而大大扩展了机会。

According to a 2024 consumer survey, 82% of expectant parents want to know the baby's sex before delivery, and the majority – two to one[2] – said they would prefer to buy a test in-store vs. ordering online.[3] Today's expecting parents want to know fetal sex sooner than ever, for preparedness, naming, nursery and registries, as well as bonding and reduced stress.

根据2024年的一项消费者调查,82%的期待中的父母希望在分娩前知道宝宝的性别,大多数-两比一[2]--表示他们更愿意在店内购买测试,而不是线上下单[3]。今天的准父母希望尽早了解胎儿的性别,以备万全,取名,装修和注册信息,以及加强亲子关系和减少压力。

"Our commitment to supporting new families is about providing trusted, affordable and accessible solutions that empower expectant parents with information when and where they want it," said Melissa Gonzales, president of women's health, Myriad Genetics. "By expanding access of the SneakPeek test through national retail partners, we're making it easier for more families to experience the meaningful moment of gender discovery and plan and prepare for parenthood."

"Our commitment to supporting new families is about providing trusted, affordable and accessible solutions that empower expectant parents with information when and where they want it," said Melissa Gonzales, president of women's health, Myriad Genetics. "By expanding access of the SneakPeek test through national retail partners, we're making it easier for more families to experience the meaningful moment of gender discovery and plan and prepare for parenthood."

The retail launch kicks off a product rebrand, new packaging design, and a website centered on the moment of gender discovery as the first key moment of parental bonding with a baby, which are scheduled for 2025. The brand's new tagline - Plan for Joy - celebrates the magical moments of joy and connection amidst all the challenges of pregnancy. Learning your baby's gender is one of the most exciting parts of pregnancy, and the SneakPeek test helps make that possible. SneakPeek is the only at-home test with over 99% accuracy in detecting a baby's gender as early as 6 weeks into pregnancy, clinically proven by peer-reviewed, published scientific studies.

The retail launch kicks off a product rebrand, new packaging design, and a website centered on the moment of gender discovery as the first key moment of parental bonding with a baby, which are scheduled for 2025. The brand's new tagline - Plan for Joy - celebrates the magical moments of joy and connection amidst all the challenges of pregnancy. Learning your baby's gender is one of the most exciting parts of pregnancy, and the SneakPeek test helps make that possible. SneakPeek is the only at-home test with over 99% accuracy in detecting a baby's gender as early as 6 weeks into pregnancy, clinically proven by peer-reviewed, published scientific studies.

Since 2015, the SneakPeek test has offered expectant families an easy and convenient non-invasive test available to order online and via doctor's offices to learn the sex of their baby. In 2022, Myriad Genetics acquired SneakPeek's parent company, Gateway Genomics, with a shared goal of expanding consumer access to the innovative at-home fetal sex test through retail partnerships.

Since 2015, the SneakPeek test has offered expectant families an easy and convenient non-invasive test available to order online and via doctor's offices to learn the sex of their baby. In 2022, Myriad Genetics acquired SneakPeek's parent company, Gateway Genomics, with a shared goal of expanding consumer access to the innovative at-home fetal sex test through retail partnerships.

How the Test Works
The retail test kit includes the patented SneakPeek Snap device, which is placed on the user's upper arm to nearly painlessly collect a blood sample with the simple press of a button. The sample is then mailed to the SneakPeek laboratory in the included, postage-paid envelope. Test results are delivered as early as the same day the sample is received through a celebratory text message and email.

测试的工作原理
零售测试套件包括专利的SneakPeek Snap设备,该设备被放置在用户的上臂上,通过简单按下一个按钮几乎无痛地收集血样。 然后将样本通过随附的预付邮件信封邮寄到SneakPeek实验室。 测试结果将在收到样本的当天通过庆祝性短信和电子邮件发送。

The SneakPeek test is now available in Walmart, Walgreens and CVS stores. Click here to find a store near you.

SneakPeek测试现在可在沃尔玛、沃尔格林和CVS商店购买。 点击此处查找您附近的商店。

About SneakPeek
Through the SneakPeek test, Myriad Genetics is on a mission to make DNA-based prenatal information affordable and accessible for all families. For more information, visit sneakpeektest.com and follow the brand on Instagram and Facebook.

关于SneakPeek
通过SneakPeek测试,万基遗传正在致力于使基于DNA的产前信息对所有家庭都能负担得起并易于获取。欲了解更多信息,请访问 sneakpeektest.com 并关注该品牌 包括提供反映我们世界多样性的创新临床试验,并努力确保我们的药品具有可扩展性和可负担性。Facebook.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .

关于Myriad Genetics
万基遗传是一家领先的基因检测和精准医学公司,致力于推进所有人的健康和福祉。万基遗传开发并提供基因检测,帮助评估发病风险或疾病进展,并指导治疗决策,涉及医疗专业领域的基因洞察可以显著改善患者护理,并降低医疗保健成本。欲了解更多信息,请访问。

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company expects that SneakPeek's expansion into retailers in the United States will improve the products affordability and accessibility so that the test may be available to many more families who want to learn the sex of their baby at-home as early as six weeks into pregnancy and that a product rebrand, new packaging design, and a website centered on the moment of gender discovery are scheduled for launch in 2025. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

免责声明
本新闻稿包含《1995年私人证券诉讼改革法案》的“前瞻性声明”,其中包括公司预计SneakPeek进入美国零售商将提高产品的价格实惠性和可及性,从而使该测试可供更多希望在怀孕六周时就能在家了解宝宝性别的家庭,而且计划于2025年推出产品重新品牌、新包装设计以及以性别发现时刻为中心的网站。这些“前瞻性声明”是管理层针对今日后事的期望,并受到已知和未知风险和不确定性的影响,可能导致实际结果、状况和事件与预期有实质和不利的不同。这些因素包括公司在美国证券交易委员会向美国证券交易委员会提交的风险描述中所描述的风险,包括公司于2024年2月28日提交的年度报告表格10-k,以及公司在不时提交的季度报告表格10-Q或当前报告表格8-k中针对这些风险因素的任何更新。Myriad公司无需且明确否认有义务更新或更改任何前瞻性声明,除非法律要求。

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

投资者联系人
马特·斯卡洛
(801) 584-3532
IR@myriad.com

Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com

媒体联系
Glenn Farrell
(385) 318-3718
PR@myriad.com

[1] In a 2021 laboratory test, SneakPeek accurately determined fetal sex in 99.02% of 102 pregnant women using the Snap device at 8-15 weeks gestational age. In a separate published study run in 2021, fetal sex was accurately determined in 100% of 134 pregnant women at 7 weeks gestational age. In a 2022 scientific study, SneakPeek accurately determined fetal sex for 100% of 103 women at 6 weeks gestational age.
[2] Gateway Genomics Research, August 2022; n=200.
[3] January 2024 Padilla Newsmaker Online Survey of 1,000 women age 21-45 who are trying to conceive, pregnant or have been pregnant.

[1] 在2021年的实验室测试中,SneakPeek在孕8-15周的102名孕妇中使用Snap设备准确地确定了胎儿性别,准确率为99.02%。另一项2021年发表的研究表明,在孕7周的134名孕妇中,胎儿性别被准确确定。在2022年的科学研究中,SneakPeek在孕6周的103名女性中准确确定了胎儿性别。
[2] Gateway Genomics研究,2022年8月;n=200。
[3] 2024年1月Padilla Newsmaker在线调查涉及1000名21-45岁的妇女,她们正在尝试怀孕、怀孕或曾怀孕。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发